Crossmark

Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

Crossref DOI link: https://doi.org/10.1186/s12885-018-4664-3

Published Online: 2018-08-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Offman, Judith

Muldrew, Beth

O’Donovan, Maria

Debiram-Beecham, Irene

Pesola, Francesca

Kaimi, Irene

Smith, Samuel G.

Wilson, Ashley

Khan, Zohrah

Lao-Sirieix, Pierre

Aigret, Benoit

Walter, Fiona M.

Rubin, Greg

Morris, Steve

Jackson, Christopher

Sasieni, Peter

Fitzgerald, Rebecca C.
Funding

Funding for this research was provided by:

Cancer Research UK (C14478/A21047, C8161/A16892, C8162/A16893, C42785/A17965)

Medical Research Council (RG84369, U105260566)

National Institute for Health Research (RG 68235)
License Information

Text and Data Mining valid from 2018-08-03
More Information

Article History

Received: 8 March 2018

Accepted: 10 July 2018

First Online: 3 August 2018

Ethics approval and consent to participate

: Ethics approval was given by the East of England – Cambridge East Ethics Committee, reference 16/EE/0546. Consent procedures are explained in detail in the Methods section, pages 6/7. In brief, written informed consent will be obtained from all participants receiving a Cytosponge™–TFF3 test or endoscopy.

: Not applicable.

: RCF and MOD hold patents on the Cytosponge technology, which has been licenced by MRC Technology to Covidien GI Solutions (now Medtronic). MOD holds a consulting contract with Medtronic. The remaining authors declare that they have no competing interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below